Moderna Inc., Johnson & Johnson and the partnership of Pfizer Inc. and BioNTech SE cleared in record time. Now the agency is charged with considering the administration’s booster program, which is set to roll out additional shots for most U.S.
vaccinated adults Sept. 20. “We are confident in the expertise and ability of our staff to continue our critical public health work, including evaluating COVID-19 vaccines," FDA spokesperson Stephanie Caccomo said in a statement.
The search for the next office director will begin imminently, Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, said in the email to staff.